伊立替康联合替吉奥、雷替曲塞或氟尿嘧啶治疗进展期胃癌的临床观察

发布时间：2018-04-19 01:09

本文选题：伊立替康 + 替吉奥　；参考：《中国药房》2017年11期

【摘要】：目的:观察伊立替康联合替吉奥、雷替曲塞或氟尿嘧啶治疗进展期胃癌的临床疗效和安全性。方法:选取2013年5月—2016年5月我院收治的一线方案治疗失败的进展期胃癌患者100例为研究对象。按照随机数字表法分为观察组(n=32)、对照A组(n=33)和对照B组(n=35)。观察组患者给予盐酸伊立替康注射液180 mg/m2,ivgtt(d1)+替吉奥胶囊60 mg/m2,po,bid(餐后)治疗,2周为1个周期;对照A组患者给予盐酸伊立替康注射液180 mg/m2,ivgtt(d1)+注射用雷替曲塞3 mg/m2,ivgtt(d1,15 min),3周为1个周期;对照B组患者给予盐酸伊立替康注射液180 mg/m2,ivgtt(d1)+亚叶酸钙注射液200 mg/m2,ivgtt(d1)+氟尿嘧啶注射液400 mg/m2,iv+2 400~3 000 mg/m2,ivgtt(46 h),d1,2周为1个周期。观察组和对照A组患者均治疗2个周期,之后第7天进行疗效评价;对照B组患者治疗3个周期,之后第12天进行疗效评价。观察3组患者临床疗效和不良反应发生情况。结果:对照A组患者脱落1例,对照B组患者脱落2例,最终纳入统计的合格病例数为97例,其中观察组32例、对照A组32例、对照B组33例。观察组患者的总缓解率(53.13%)明显高于对照A组(43.75%)和对照B组(36.36%),观察组患者的总控制率(81.25%)明显高于对照A组(68.75%)和对照B组(57.58%),差异均有统计学意义(P0.05)。3组患者不良反应发生率比较,差异均无统计学意义(P0.05)。结论:伊立替康联合替吉奥治疗进展期胃癌患者的临床疗效较伊立替康联合雷替曲塞或氟尿嘧啶更好,且安全性较好。
[Abstract]:Aim: to observe the clinical efficacy and safety of irinotecan combined with tetigol, retitrexed or fluorouracil in the treatment of advanced gastric cancer.Methods: from May 2013 to May 2016, 100 patients with advanced gastric cancer who failed in first-line treatment were selected.According to the method of random number table, the observation group was divided into two groups: observation group (n = 32), control group A (n = 35) and control group B (n = 35).The patients in the observation group were treated with Ilytecan Hydrochloride injection 180 mg / m 2 iv / d 1) tigeo capsule 60 mg / m 2 pobido (postprandial) was treated for 2 weeks, and the control group A group was treated with the injection 180 mg / m 2 / d iv gttd1) for a period of 3 mg / m 2 iv gtttd1 / 15 min for a period of 15 min. The patients in the control group were treated with Irititecan Hydrochloride injection 180 mg / m 2 / d iv gttd1) for 3 weeks, and the control group was given the injection of Ilytecan Hydrochloride 180 mg / m 2 / d iv gttd1 for 15 min.In control group B, patients were given Ilitecan Hydrochloride 180 mg / m2 iv / d 1) calcium folate injection 200 mg / m 2 iv iv 2 400 mg / m 2 / d 2 iv 2 400 mg / m 2 / d 1.Observation group and control group A patients were treated for 2 cycles, and then 7 days to evaluate the efficacy, control group B patients treated for 3 cycles, then 12 days to evaluate the efficacy.The clinical efficacy and adverse reactions were observed in three groups.Results: there were 1 case in control group A and 2 cases in control group B. 97 eligible cases were included in the statistics, including 32 cases in observation group, 32 cases in control group A and 33 cases in control group B.The total remission rate of observation group (53.13) was significantly higher than that of control group A (43.75) and control group B (36.36%), and the total control rate of observation group (81.25) was significantly higher than that of control group A (68.75%) and control group B (57.58%).The difference was not statistically significant (P 0.05).Conclusion: the clinical efficacy of irinotecan combined with tigualone in the treatment of advanced gastric cancer is better than that of irinotecan combined with retitrexil or fluorouracil, and the safety is better than that of irinotecan combined with rititrexide or fluorouracil.
【作者单位】：安阳市第六人民医院普外科;
【分类号】：R735.2

【参考文献】